Follow The Short Interest: What Next for Vical (NASDAQ:VICL) Stock After Increase in Shorted Shares?

November 18, 2016 - By Darrin Black   ·   0 Comments

Follow The Short Interest: What Next for Vical (NASDAQ:VICL) Stock After Increase in Shorted Shares?

The stock of Vical (NASDAQ:VICL) registered an increase of 77.02% in short interest. VICL’s total short interest was 43,900 shares in November as published by FINRA. Its up 77.02% from 24,800 shares, reported previously. With 22,500 shares average volume, it will take short sellers 2 days to cover their VICL’s short positions. The short interest to Vical’s float is 0.51%. About 58,095 shares traded hands or 49.69% up from the average. Vical Incorporated (NASDAQ:VICL) has declined 36.50% since April 18, 2016 and is downtrending. It has underperformed by 40.93% the S&P500.

Vical Incorporated researches and develops biopharmaceutical products based on its deoxyribonucleic acid delivery technologies for the prevention and treatment of life-threatening diseases. The company has a market cap of $27.74 million.

VICL Company Profile

Vical Incorporated, incorporated on April 30, 1987, researches and develops biopharmaceutical products based on its deoxyribonucleic acid (DNA) delivery technologies for the prevention and treatment of serious or life-threatening diseases. The Firm has approximately four active, independent, or partnered development programs in the areas of infectious disease including a Phase III clinical trial of ASP0113 for prevention of cytomegalovirus (CMV) reactivation in stem cell transplant recipients and Phase II clinical trial of ASP0113 for prevention of CMV infection in kidney transplant recipients; Phase I/II clinical trial of its therapeutic genital herpes vaccine, designed to reduce viral shedding and genital herpes lesions in herpes simplex virus type 2 (HSV-2) infected patients; an ongoing Phase I program of VL-2397 for invasive fungal infections, including invasive Aspergillus, which are causes of morbidity and mortality in immunocompromised patients, including transplant recipients, and a completed preclinical program, with an allowed investigational new drug application (IND) using its CyMVectin prophylactic vaccine formulated with its Vaxfectin adjuvant to prevent CMV infection before and during pregnancy.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By Darrin Black


Readers Comments (0)





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>